A. Norton
Royal Marsden NHS Foundation Trust · 17 works · 843 citations · h-index 9
Top works
- Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
- Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma
- A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial
- The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma
- Serum p53 antibodies: predictors of survival in small-cell lung cancer?
- Time and chemotherapy treatment trends in the treatment of elderly patients (age ⩾70 years) with small cell lung cancer
- Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma
- Time and Chemotherapy Treatment Trends in the Treatment of Elderly Patients (Age ≥ 70 Years) with Non-small Cell Lung Cancer
- Addition of SRL 172 to standard chemotherapy in small cell lung cancer (SCLC) improves symptom control
- Mitomycin C, Vinblastine and Carboplatin: Effective Outpatient Chemotherapy for Advanced Non-Small Cell Carcinoma of the Lung (NSCLC)
- O-28 The use of mitomycin C, vinblastine, and cisplatin (MVP) chemotherapy in patients with malignant mesothelioma — Outcome and predictive factors
- P-596 Chemotherapy treatments outcome and toxicities in the treatmentof elderly patients (age ⩾ 70) with lung cancer
- P-841 A pilot study to assess the incidence of constipation in patientsreceiving vinca-alkaloid chemotherapy for lung cancer and to evaluate their self-care actions
- Early response to platinum-based chemotherapy in non small cell lung cancer (NSCLC) predicts survival
- PD-082 Early response to platinum-based chemotherapy in nonsmall cell lung cancer (NSCLC) predicts survival unluike in mesotheliomas
- O-079 Early versus delayed chemotherapy in symptomatically stableor asymptomatic patients with malignant mesothelioma — A randomised trial with survival and quality of life data